CoChat

An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke

Open access

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

Diabetes is a major risk factor for the development of stroke. Glucagon-like peptide-1 receptor (GLP-1R) agonists have been in clinical use for the treatment of diabetes and also been reported to be neuroprotective in ischemic stroke. The quinoxaline 6,7-dichloro-2-methylsulfonyl-3-N-tert- butylaminoquinoxaline (DMB) is an agonist and allosteric modulator of the GLP-1R with the potential to increase the affinity of GLP-1 for its receptor. The aim of this study was to evaluate the neuroprotective effects of DMB on transient focal cerebral ischemia. In cultured cortical neurons, DMB activated the GLP-1R, leading to increased intracellular cAMP levels with an EC50 value about 100 fold that of exendin-4. Pretreatment of neurons with DMB protected against necrotic and apoptotic cell death was induced by oxygen-glucose deprivation (OGD). The neuroprotective effects of DMB were blocked by GLP-1R knockdown with shRNA but not by GLP-1R antagonism. In C57BL/6 mice, DMB was orally administered 30 min prior to middle cerebral artery occlusion (MCAO) surgery. DMB markedly reduced the cerebral infarct size and neurological deficits caused by MCAO and reperfusion. The neuroprotective effects were mediated by activation of the GLP-1R through the cAMP-PKA-CREB signaling pathway. DMB exhibited anti-apoptotic effects by modulating Bcl-2 family members. These results provide evidence that DMB, a small molecular GLP-1R agonist, attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO. Taken together, these data suggest that DMB is a potential neuroprotective agent against cerebral ischemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0148827

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Structure of DMB, molecular formula C13H15Cl2N3O2S.
Fig 1 Structure of DMB, molecular formula C13H15Cl2N3O2S.CC BY · PubMed Central
Fig 2 DMB activates the GLP-1 receptor in cortical neurons. (A) Western blot showing GLP-1R expression in neurons and β-cells. (B) Bar graph reflecting the GLP-1R expression in each group. Data are presented as percentage of β-cells. n = 5 (C) cAMP stimulation by DMB (1 μM) in neurons and detected 0–30 min after incubation. Data are expressed as percentage of 0 min. n = 6.
Fig 2 DMB activates the GLP-1 receptor in cortical neurons. (A) Western blot showing GLP-1R expression in neurons and β-cells. (B) Bar graph reflecting the GLP-1R expression in each group. Data are presented as percentage of β-cells. n = 5 (C) cAMP stimulation by DMB (1 μM) in neurons and detected 0–30 min after incubation. Data are expressed as percentage of 0 min. n = 6.CC BY · PubMed Central
Fig 3 DMB and exendin-4 activate the GLP-1R in neurons by different mechanisms. (A) DMB and exendin-4 show different responses in the presence of exendin (9–39) or LV-shGLP-1R. (B) cAMP was stimulated in neurons by exendin-4 (100 nM), DMB (10 μM) and/or GLP-1 (100 nM). cAMP was detected 15 min after incubation. ex (9–39): exendin(9–39), data are expressed as a percentage of cAMP stimulation induced by 1 mM GLP-1. ** p < 0.01.
Fig 3 DMB and exendin-4 activate the GLP-1R in neurons by different mechanisms. (A) DMB and exendin-4 show different responses in the presence of exendin (9–39) or LV-shGLP-1R. (B) cAMP was stimulated in neurons by exendin-4 (100 nM), DMB (10 μM) and/or GLP-1 (100 nM). cAMP was detected 15 min after incubation. ex (9–39): exendin(9–39), data are expressed as a percentage of cAMP stimulation induced by 1 mM GLP-1. ** p < 0.01.CC BY · PubMed Central
Fig 4 DMB increased cortical neuron survival in OGD and reperfusion. (A) Quantification of cell viability in each group by MTT. n = 6. (B) Quantification of cell survival in each group by LDH. n = 6. (C) Image of Hoechst and PI staining in cortical neurons. Scale bar = 25 μm. (D) Bar graph reflects percentage of apoptotic neurons following OGD or normoxia. Six different fields were counted. ** p < 0.01.
Fig 4 DMB increased cortical neuron survival in OGD and reperfusion. (A) Quantification of cell viability in each group by MTT. n = 6. (B) Quantification of cell survival in each group by LDH. n = 6. (C) Image of Hoechst and PI staining in cortical neurons. Scale bar = 25 μm. (D) Bar graph reflects percentage of apoptotic neurons following OGD or normoxia. Six different fields were counted. ** p < 0.01.CC BY · PubMed Central
Fig 5 Effects of DMB on plasma insulin and glucose levels. DMB (5 μmol/kg) was orally administered to C57BL/6 mice. Insulin and glucose levels were detected at 0, 30, 60, 90 and 120 min after administration. (A) Plasma insulin levels. (B) Blood glucose levels. n = 6.
Fig 5 Effects of DMB on plasma insulin and glucose levels. DMB (5 μmol/kg) was orally administered to C57BL/6 mice. Insulin and glucose levels were detected at 0, 30, 60, 90 and 120 min after administration. (A) Plasma insulin levels. (B) Blood glucose levels. n = 6.CC BY · PubMed Central
Fig 6 DMB treatment improved neurological deficit and decreased infarct volume 24 h after MCAO. (A) Neurological deficit scores. n = 8. (B) Photographs of brain slices stained with TTC. (C) Quantitative analysis of infarct volume. n = 6. * p < 0.05, ** p < 0.01.
Fig 6 DMB treatment improved neurological deficit and decreased infarct volume 24 h after MCAO. (A) Neurological deficit scores. n = 8. (B) Photographs of brain slices stained with TTC. (C) Quantitative analysis of infarct volume. n = 6. * p < 0.05, ** p < 0.01.CC BY · PubMed Central
Fig 7 Effects of DMB on the cAMP-PKA-CREB signaling pathway after MCAO. (A) Western blot analysis of PKA, p-CREB and CREB in ipsilateral ischemic penumbra 24 h post MCAO or sham operation. (B-D) Bar graphs reflect PKA, p-CREB and CREB proteins in each group. Data are expressed as a percentage of sham. n = 6. ** p < 0.01.
Fig 7 Effects of DMB on the cAMP-PKA-CREB signaling pathway after MCAO. (A) Western blot analysis of PKA, p-CREB and CREB in ipsilateral ischemic penumbra 24 h post MCAO or sham operation. (B-D) Bar graphs reflect PKA, p-CREB and CREB proteins in each group. Data are expressed as a percentage of sham. n = 6. ** p < 0.01.CC BY · PubMed Central
Fig 8 DMB treatment decreased neuronal apoptosis in cerebral ischemia. (A) TUNEL assay 24 h post MCAO or sham operation. Photographs were taken from ipsilateral ischemic penumbra area. Scale bar = 25 μm. (B) Bar graph reflects the number of TUNEL-positive neurons in each group. Six different fields were counted. (C) Western blot assay of Bax and Bcl-2 expression in ipsilateral ischemic penumbra area 24 h post MCAO or sham operation. (D) Bar graph reflects Bax/Bcl-2 ratio in each group. n = 6. ** p < 0.01.
Fig 8 DMB treatment decreased neuronal apoptosis in cerebral ischemia. (A) TUNEL assay 24 h post MCAO or sham operation. Photographs were taken from ipsilateral ischemic penumbra area. Scale bar = 25 μm. (B) Bar graph reflects the number of TUNEL-positive neurons in each group. Six different fields were counted. (C) Western blot assay of Bax and Bcl-2 expression in ipsilateral ischemic penumbra area 24 h post MCAO or sham operation. (D) Bar graph reflects Bax/Bcl-2 ratio in each group. n = 6. ** p < 0.01.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 52

Metadata

Authors
Zhang, H., Liu, Y., Guan, S., Qu, D., Wang, L., Wang, X., Li, X., Zhou, S., Zhou, Y., Wang, N., Meng, J., & Ma, X.
Affiliations
Air Force Medical University (CN)
Corresponding author
  • Meng, Jingru
  • Ma, Xue
Venue
PLOS ONE
Published
2016-02-10
Volume
11
Issue
2
Pages
e0148827
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2265017848
Cited by
50
References
44
Citations by year
2026: 4 · 2025: 3 · 2024: 7 · 2023: 3 · 2022: 4 · 2021: 3 · 2020: 8 · 2019: 4 · 2018: 8 · 2017: 5 · 2016: 1
FWCI
3.47
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (81402931, 81471093, 81571278)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
GLP-1 receptor, allosteric agonists, DMB, neuroprotection, cerebral ischemia, ischemic stroke, middle cerebral artery occlusion, oxygen-glucose deprivation, neuronal apoptosis, cAMP/PKA/CREB signaling, Bcl-2 family proteins, oral administration, diabetes mellitus
MeSH terms
Glucagon-Like Peptide-1 Receptor, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Allosteric Regulation, Animals, Blood Glucose, Brain, Cell Survival, Cells, Cultured, Drug Evaluation, Preclinical, Insulin, Male, Mice, Inbred C57BL, Neurons, Peptides, Quinoxalines, Sulfones, Venoms, Reperfusion Injury, Apoptosis, Neuroprotective Agents, Inhibitory Concentration 50, Infarction, Middle Cerebral Artery, Primary Cell Culture

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke. https://app.cochat.ai/papers/10.1371/journal.pone.0148827
The paper
Zhang, H., Liu, Y., Guan, S., Qu, D., Wang, L., Wang, X., Li, X., Zhou, S., Zhou, Y., Wang, N., Meng, J., & Ma, X. (2016). An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke. PLOS ONE. https://doi.org/10.1371/journal.pone.0148827

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.